Silo Pharma Inc SILO
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2012-01-05 |
| Shares Out. | 1,250,000 |
| Website | silopharma.com/ ↗ |
| Phone | 17184009031 |
| Employees | 3 |
| Revenue | $18,026 |
| Gross Profit | -$2,662 |
| Net Income | -$1.6M |
| Total Assets | $7.0M |
| Total Liabilities | $1.3M |
| Equity | $5.7M |
About Silo Pharma Inc
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.
Silo Pharma Inc is a publicly traded company under the ticker symbol SILO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2025-03-01)